SCHEMBL6850815

SCHEMBL6850815

SC/C=C/c1cnc2ccccc2c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 4/20 0.67
PDGFRA P16234 4/20 0.67
RAB9A P51151 3/20 0.58
KDM4E B2RXH2 2/20 0.52
KMT2A Q03164 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
CYP1A2 P05177 1/20 0.46
ALDH1A1 P00352 5/20 0.44
GAA P10253 2/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
MGAM O43451 1/20 0.41
ADORA2A P29274 1/20 0.41
CYP2A6 P11509 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6850823 1.00 PDGFRB (0.67) PDGFRBPDGFRARAB9AKDM4EKMT2A
SCHEMBL7117727 0.83 PDGFRB (0.67) PDGFRBPDGFRARAB9AKDM4EKMT2A
SCHEMBL372028 0.83 PDGFRB (0.67) PDGFRBPDGFRARAB9AKDM4EKMT2A
SCHEMBL372029 0.83 PDGFRB (0.67) PDGFRBPDGFRARAB9AKDM4EKMT2A
SCHEMBL3906668 0.83 PDGFRB (0.67) PDGFRBPDGFRARAB9AKDM4EKMT2A
SCHEMBL4872097 0.83 PDGFRB (0.67) PDGFRBPDGFRARAB9AKDM4EKMT2A
SCHEMBL3906662 0.83 PDGFRB (0.67) PDGFRBPDGFRARAB9AKDM4EKMT2A
SCHEMBL372262 0.83 PDGFRB (0.67) PDGFRBPDGFRARAB9AKDM4EKMT2A
SCHEMBL10162435 0.83 PDGFRB (0.67) PDGFRBPDGFRARAB9AKDM4EKMT2A
SCHEMBL2056162 0.83 PDGFRB (0.67) PDGFRBPDGFRARAB9AKDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6825170-B2 ERYTHROMYCIN TYPE MACROLIDE WITH A FUSED OXAZOLONE RING ORTHO-MCNEIL PHARMACEUTICAL, INC. 2004-11-30 US disclosed
EP-1453847-A1 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS Ortho-Mcneil Pharmaceutical, Inc. (US) 2004-09-08 EP disclosed
US-20030220272-A1 6-O-acyl ketolide antibacterials ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-11-27 US disclosed
WO-2003050132-A1 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2003-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220272-A1 6-O-acyl ketolide antibacterials Q6ZSR9, ACSL6, RPS4Y1 PDGFRB 4783/4885PDGFRA 4442/4885RAB9A 982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.